Company / Net Debt per Share
Regeneron Pharmaceuticals Net Debt per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$9.96
FY2025
5-year range
-$9.96 / -$1.86
FY2021-FY2025
Trend
-124.3%
vs FY2024
Sector context
#80 of 82
Health Care
What the data says
Among 82 Health Care companies, Regeneron Pharmaceuticals is in the top 2% for net debt per share. Net Debt per Share has fluctuated over the past 7 years, ranging from $-13.96 in FY2019 to $3.14 in FY2020.
Based on SEC 10-K filings.
-9.96 in FY2025.
Improved from $-6.66 to $-9.96 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 82This company -$9.96 Sector average $13.70
▼
-172.7% below sector average
Key checks
Key Insights
- In FY2025, net debt per share decreased 124.3% year-over-year.
- Ranks #80 out of 82 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2020.
- Lowest net debt per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$9.96 | -124.3% |
| FY2024 | -$4.44 | +33.3% |
| FY2023 | -$6.66 | +15.2% |
| FY2022 | -$7.86 | -321.3% |
| FY2021 | -$1.86 | -159.3% |
| FY2020 | $3.14 | +122.5% |
| FY2019 | -$13.96 | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026